Expert Interview
A Second Look: Examining Morphosys' pelabresib in anticipation of the phase 3 MANIFEST trial results and other bromodomain and extra-terminal (BET) inhibitors being developed for myelofibrosis.
Ticker(s): MORInstitution: Vanderbilt University Medical Center
- Assistant Professor of Medicine, Hematology/Oncology at Vanderbilt University Medical Center.
- Manages 60 patients with Myelofibrosis.
- Completed fellowship in experimental therapeutics from Taussig Cancer institute in 2021 and research focuses on cancer biology.
Roughly how many patients do you currently manage with myelofibrosis?
Added By: dami_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for pelabresib?
Added By: dami_adminWhat proportion of your patients are indolent, intermediate, or high-risk?
Added By: slingshot_insightsCan you walk us through the current treatment algorithm for myelofibrosis?
What percentage of your patients are on ruxolitinib as a first-line treatment?
Have you used momelotinib as a first-line setting?Can you clarify your rationale to use momelotinib in the first-line?
How many patient overlaps between pacritinib and momelotinib?
What are your thoughts on pelabresib's mechanism of action for myelofibrosis?
What do you expect from the MANIFEST-2 data?
What's the minimum bar for pelabresib to get FDA approval?
How do you compare navitoclax with pelabresib? Are you familiar with BMS-158?
What are your thoughts on selinexor in combination with ruxolitinib?
How do you see the future of combo therapies for myelofibrosis?
Added By: slingshot_insightsOn a scale from 1 to 10, how excited are you about pelabresib?
Added By: slingshot_insightsIs there any molecular signature to guide clinicians in using the four JAK inhibitors?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
